Drug Trial Radar · NCT02153502
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
206
Actual
Start
Jul 1, 2014
Primary completion
Feb 1, 2016
Study completion Feb 1, 2016
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Jun 3, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this 10-week study are to evaluate the efficacy, safety, and tolerability of AVP 786 as an adjunctive therapy compared with placebo in patients with major depressive disorder (MDD) who have shown an inadequate response to standard antidepressant treatment. A secondary objective of this study is to assess the pharmacokinetics (PK) of AVP-786 and potential correlations with pharmacodynamic effects.
Conditions
- Depressive Disorder, Treatment-Resistant
Interventions
AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)Drug
AVP-786 capsules administered orally.
PlaceboDrug
Matching placebo capsules administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Montgomery-Ǻsberg Depression Rating Scale (MADRS) total scoreTime frame: Visit 5 (Day 70) Week 10
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Birmingham, Alabama
Site not named
Bellflower, California
Site not named
Costa Mesa, California
Site not named
Garden Grove, California
Site not named
Lomita, California
Site not named
Oceanside, California
Site not named
Riverside, California
Site not named
Santa Ana, California
Site not named
Sherman Oaks, California
Site not named
Denver, Colorado
Site not named
Bradenton, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Orange City, Florida
Site not named
Orlando, Florida
Site not named
Decatur, Georgia
Site not named
Hoffman Estates, Illinois
Site not named
Valparaiso, Indiana
Site not named
Baltimore, Maryland
Site not named
Glen Burnie, Maryland
Site not named
Boston, Massachusetts
Site not named
Brooklyn, New York
Site not named
New York, New York
Site not named
Staten Island, New York
Site not named
Garfield Heights, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Oklahoma City, Oklahoma
Site not named
Tulsa, Oklahoma
Site not named
Philadelphia, Pennsylvania
Site not named
Philadelphia, Pennsylvania
Site not named
Murray, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.